Page 19 - U11248 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from U11248. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In U11248 Today - Breaking & Trending Today

Skinny-Label Biosimilars Provide Substantial Savings to Medicare

The estimated savings to Medicare during 2015-2020 that resulted from competition with five of the first-to-market biosimilars with skinny labels was $1.5 billion. ....

United States , Alexanderc Egilman , Robert Steinbrook , Drug Administration , Harvard Medical School , Medicine Editorial Fellow Eric Ward , Medicine Editor , Online Editor Robert Steinbrook , Federal Circuit , First Amendment , Biologic Therapy , Biosimilar Drugs , Follow On Biologics , Generic Drug , Eneric Medication , Angiogenesis Inhibitor , Nhibitor Angiogenesis , Antineoplastic Drug , Nti Cancer Agents , Beta Adrenergic Agonists , Cardiovascular Imaging , Ardiac Imaging , Iv Im ,

Managing T-DXd Adverse Events in the Real World

Managing adverse events with trastuzumab deruxtecan (Enhertu) in real-world clinical practice is proving trickier than would have been anticipated from clinical trial reports. ....

United States , Mayo Clinic In Rochester , San Francisco , Sid Yadav , University Of California , Mayo Clinic , Medscape Medical , Hope Rugo , Breast Cancer , Alignant Breast Neoplasm , Biologic Therapy , Antineoplastic Drug , Nti Cancer Agents , Small Cell Lung Cancer , Lung Cancer , Ung Carcinoma , Ancer Lung , Healthcare And Medical Technology , Ealth And Medical Tech , Ealth And Med Tech , Ealth And Medical Technology ,

FDA Rejects Piziotinib for Certain Types of NSCLC

The drug was not approved for the treatment of patients with previously treated locally advanced or metastatic nonsmall cell lung cancer harboring HER2 exon 20 insertion mutations. ....

Richard Pazdur , Harpreet Singh , Oncologic Drugs Advisory Committee , University Of Maryland School Medicine , Spectrum Pharmaceuticals , Drug Administration , Drug Development , Drugs Advisory Committee , Medscape Medical , Tom Riga , Maryland School , Lung Cancer , Ung Carcinoma , Ancer Lung , Biologic Therapy , Non Small Cell Lung Cancer , Alignant Neoplasia , Humanized Monoclonal Antibody , Tyrosine Kinase Inhibitor , Us Food And Drug Administration , Nited States Food And Drug Administration ,

CTD-ILD: Rituximab 'a Reasonable Alternative to Cyclophosphamide'

A clinical trial found that rituximab and cyclophosphamide had similar outcomes for interstitial lung disease associated with connective tissue disorders. ....

United Kingdom , City Of , United States , Los Angeles , Oliver Distler , Toby Maher , University Hospital , Imperial College London , American College Of Rheumatology , University Of Southern California , Southern California , American College , Lancet Respiratory , Imperial College , Biologic Therapy , Antineoplastic Drug , Nti Cancer Agents , Interstitial Lung Disease , Drug Treatment Safety , Connective Tissue Disease , Mixed Connective Tissue Disease , Mixed Connective Tissue Disease , Sharp Syndrome , Clinical Research , Clinical Trials , Linical Studies ,

What Role Now for Margetuximab in HER2 Breast Cancer?

In the final report of a phase 3 trial, there was no overall survival advantage with margetuximab vs trastuzumab. ....

San Diego , United States , San Francisco , Bijoy Telivala , Rebecca Shatsky , Kathy Miller , Indiana University , Napo Pharmaceuticals , University Of California , Macrogenics Inc , Drug Administration , Hope Rugo , Cancer Specialists , North Florida , Breast Cancer , Alignant Breast Neoplasm , Antineoplastic Drug , Nti Cancer Agents , Biologic Therapy , Humanized Monoclonal Antibody , Metastatic Breast Carcinoma , Alignant Neoplasia , Genomic Medicine , Edicine Genomic ,